Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 1/20 | 0.44 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HTR5A | P47898 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 2/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27420495 | 0.84 | PDK2 (0.43) | PDK2PDK4ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL6221516 | 0.79 | PDK2 (0.46) | PDK2PDK4ALDH1A1HTR5AMAPT | |
| SCHEMBL27388647 | 0.76 | ALDH1A1 (0.40) | PDK2PDK4ALDH1A1HTR5AMAPT | |
| SCHEMBL843154 | 0.76 | TGM2 (0.36) | ALDH1A1MAPTIDO1KMT2AMEN1 | |
| SCHEMBL843002 | 0.76 | KMT2A (0.39) | MAPTIDO1KMT2AMEN1 | |
| SCHEMBL843721 | 0.74 | PGR (0.42) | ALDH1A1KDM4E | |
| SCHEMBL842905 | 0.73 | CYP11B2 (0.51) | PDK2PDK4HTR5AL3MBTL1KMT2A | |
| SCHEMBL9156505 | 0.71 | PGR (0.36) | ALDH1A1HTR5AL3MBTL1KMT2AMEN1 | |
| SCHEMBL841685 | 0.70 | CYP19A1 (0.43) | PDK2PDK4HTR5A | |
| SCHEMBL1098201 | 0.69 | ALDH1A1 (0.40) | ALDH1A1MAPTL3MBTL1IDO1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143278-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-27 | — | — | US | disclosed |
| US-8143278-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-27 | — | — | US | disclosed |
| US-8143278-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-27 | — | — | US | disclosed |
| US-20100093711-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-04-15 | — | — | US | disclosed |
| US-20100093711-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-04-15 | — | — | US | disclosed |
| US-20100093711-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-04-15 | — | — | US | disclosed |
| EP-2121652-A1 | 4-IMIDAZOLYL-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE AS ALDOSTERONE/11-BETA-HYDROXYLASE INHIBITORS | Novartis AG (CH) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008076860-A1 | 4-IMIDAZOLYL-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE AS ALDOSTERONE/11-BETA-HYDROXYLASE INHIBITORS | NOVARTIS AG (CH) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008076860-A1 | 4-IMIDAZOLYL-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE AS ALDOSTERONE/11-BETA-HYDROXYLASE INHIBITORS | NOVARTIS AG (CH) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093711-A1 | ORGANIC COMPOUNDS | CYP11B1, HSD11B1, CYP11B2 | PDK2 1156/4885PDK4 485/4885ALDH1A1 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.